Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 30, 2025Acta HaematologicaOpen Access

Real World Experience of Azacitidine + Venetoclax in AML rigorously following management guidelines from clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

BSBochra SedakiAIAlexandre IatSBSami Benachour

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows azacitidine and venetoclax improve outcomes in AML patients, suggesting adherence to management guidelines is crucial.

Key Points

  • Overall survival reached 18 months in AML patients treated with azacitidine and venetoclax.
  • Complete remission rate of 51% was observed after one cycle of treatment with azacitidine plus venetoclax.
  • Rigorous adherence to management guidelines improved clinical outcomes in a real-world population of AML patients.
  • Study results align closely with findings from the VIALE-A clinical trial, emphasizing the need for guideline compliance.

Cite This Study

Sedaki et al. (2025) studied this question.

synapsesocial.com/papers/68dc1e308a7d58c25ebb15afhttps://doi.org/10.1159/000548334
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience2024 · 4 citations
  2. 2Addition of Venetoclax to Azacitidine Did Not Improve Survival in Acute Myeloid Leukemia and Was Not Well Tolerated: Real World Experience2026
  3. 3Real-life multicenter experience of long-term treatment with venetoclax plus azacitidine for acute myeloid leukemia in China2026
  4. 4Real-world evidence on the use of lower-intensity treatment with venetoclax and azacitidine in newly diagnosed AML in younger patients2026
  5. 5Allogeneic hematopoietic stem cell transplantation after azacitidine and venetoclax salvage in relapsed/refractory AML: a multicenter real-world study by the French AURAML group2026 · 1 citations